(Alliance News) - AstraZeneca PLC on Monday said a breast cancer drug failed to significantly extend patients' lives, a second blow this month to hopes for the product. Datopotamab deruxtecan, also ...
On a more positive note Astra said benralizumab, with a brand name of Fasenra, has been recommended for approval in the EU. It has been recommended as an add-on treatment for adult patients with ...